Fenwick & West LLP represented Applied Proteomics, Inc., a developer of protein-based molecular diagnostics, in its recently announced $28 million Series C financing. The round was led by Genting Berhad, with participation from existing investors Domain Associates and Vulcan Capital.
The new investment will help the company begin commercializing its novel diagnostic tools and move closer to achieving its vision of saving lives and reducing healthcare costs through precision medicine. More information about Applied Proteomics’ $28M Series C financing can be obtained from the company press release.
The Fenwick transaction team was led by corporate partners Sam Angus; and corporate associates Derek Huoth and John Chen.